Similarly as with the IL-8 results, there was no association between CCL2 concentration and an increased risk of death in brain tumor patients in the following 2 years, as chemokine levels did not differ between patients who had died compared to patients who had lived (p = 0.5261) (Fig 4). This evidence concerns the gene CXCL8 and brain neoplasm.